Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-4 tablets in postherpetic neuralgia (phase II, pregabalin-controlled)
CTR20254787Phase 2Active
- Sponsor
- Nanjing NeuroDawn Pharmaceutical
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Y-4 in postherpetic neuralgia (PHN), sponsored by Nanjing NeuroDawn Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
Y-4
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on CTR20254787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254787.